argenx SE (SA:A1RG34) — Market Cap & Net Worth
Market Cap & Net Worth: argenx SE (A1RG34)
argenx SE (SA:A1RG34) has a market capitalization of $50.32 Billion (R$256.46 Billion) as of April 17, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #462 globally and #15 in its home market, demonstrating a 8.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying argenx SE's stock price R$164.96 by its total outstanding shares 1554694275 (1.55 Billion).
argenx SE Market Cap History: 2024 to 2026
argenx SE's market capitalization history from 2024 to 2026. Data shows growth from $46.57 Billion to $50.32 Billion (0.00% CAGR).
argenx SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how argenx SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.79x
argenx SE's market cap is 13.79 times its annual revenue
Latest Price to Earnings (P/E) Ratio
44.34x
argenx SE's market cap is 44.34 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $46.57 Billion | $2.19 Billion | $833.04 Million | 21.26x | 55.90x |
| 2025 | $57.29 Billion | $4.15 Billion | $1.29 Billion | 13.79x | 44.34x |
Competitor Companies of A1RG34 by Market Capitalization
Companies near argenx SE in the global market cap rankings as of April 17, 2026.
Key companies related to argenx SE by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $110.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #292 globally with a market cap of $77.51 Billion USD.
- CSL Ltd (AU:CSL): Ranked #494 globally with a market cap of $47.22 Billion USD ( AU$66.73 Billion AUD).
- CSL Limited (F:CSJ): Ranked #513 globally with a market cap of $45.38 Billion USD ( €38.82 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.53 Billion | $435.65 |
| #292 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.51 Billion | $746.00 |
| #494 | CSL Ltd | AU:CSL | $47.22 Billion | AU$137.55 |
| #513 | CSL Limited | F:CSJ | $45.38 Billion | €82.45 |
argenx SE Historical Marketcap From 2024 to 2026
Between 2024 and today, argenx SE's market cap moved from $46.57 Billion to $ 50.32 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$50.32 Billion | -12.16% |
| 2025 | R$57.29 Billion | +23.03% |
| 2024 | R$46.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 17th, 2026 the market cap of argenx SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.32 Billion USD |
| MoneyControl | $50.32 Billion USD |
| MarketWatch | $50.32 Billion USD |
| marketcap.company | $50.32 Billion USD |
| Reuters | $50.32 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more